Publication date: Aug 06, 2021
Reference: Merck’s’ Keytruda (pembrolizumab) significantly prolonged recurrence-free survival (RFS) compared to placebo as adjuvant therapy for patients with stage II resected high-risk melanoma in phase 3 KEYNPTE-716 trial. The KEYNOTE-716 trial, which investigated the safety and efficacy of pembrolizumab for patients with surgically resected high-risk stage II melanoma, enrolled 954 patients who were 12 years or older. Patients were only eligible for the second part of the study if they had recurrence after receiving the placebo or completed 17 cycles of pembrolizumab. Patients in the pembrolizumab group who experienced disease recurrence within 6 months of completing the treatment were excluded from part 2 of the study. Pediatric patients were to receive either pembrolizumab or the placebo intravenously up to 200 mg every 3 weeks for up to 17 cycles. -Many patients with stage II melanoma have a high risk of their cancer returning after surgery. In the first part of the double-blind study adults in the pembrolizumab group received 200 mg intravenously every 3 weeks for up to 17 cycles.